164 completed, 52 recruiting, 34 terminated, 33 active not recruiting. 141 Phase 2, 76 Phase 1, 47 Not applicable, 21 Phase 3, 6 Early Phase 1.
Follow Neurofibroma: new trials by email Literature Review of Neurofibroma trials Research Report on Neurofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor) | Phase 2 | Not yet recruiting | Girish Dhall, MD | 23 | 2027-01-01 | 2026-08-04 |
| Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs) GentleMax Pro (with skin cooling), GentleMax Pro (without skin cooling) - Neurofibromatosis 1 (NF1), Neurofibromatosis Type I | Not applicable | Suspended | Massachusetts General Hospital | 10 | 2027-01-01 | 2026-06-04 |
| Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma mirdametinib with radiation, mirdametinib - Neurofibromatosis 1 (NF1) | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 55 | 2027-01-01 | 2026-10-05 |
| Cognitive Intervention for Children and Adolescents With NF1 Unstuck and On Target! - Neurofibromatosis 1 (NF1), Executive Function (Cognition) | Not applicable | Not yet recruiting | The Hospital for Sick Children | 60 | 2026-09-28 | 2026-10-13 |
| Observational Study of the Real-world Effectiveness and Safety of Selumetinib Treating Adult Patients With Neurofibromatosis Type 1 (NF1) Who Have Symptomatic, Inoperable Plexiform Neurofibroma (PN) Neurofibromatosis Type 1 (NF1) | Recruiting | AstraZeneca | 800 | 2026-09-28 | 2026-10-22 | |
| Neurocutaneous Syndromes in Children: Prevalence and Clinical Characteristics Sturge-Weber Syndrome, Neurocutaneous Syndromes | Not yet recruiting | Assiut University | 100 | 2026-09-20 | 2026-09-28 | |
| How Can the Experience of Hospital Outpatient Departments be Improved? Qualitative data collection activities - Neurofibromatosis Type 1 (NF1), NF2-related Schwannomatosis | Not yet recruiting | King's College London | 30 | 2026-09-01 | 2026-09-14 | |
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Selumetinib + ZEN-3694 ± Durvalumab - MPNST, NF1 | Phase 2 | Recruiting | University of Alabama at Birmingham | 41 | 2026-08-04 | 2026-08-24 |
| Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor BMS-986504 - Malignant Peripheral Nerve Sheath Tumors, MPNST | Phase 1 / Phase 2 | Recruiting | Ankit Mangla, MD | 17 | 2026-08-01 | 2026-08-11 |
| Gait in Young Children With NF1 Neurofibromatosis Type 1 | Not yet recruiting | NYU Langone Health | 56 | 2026-08-01 | 2026-05-08 | |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-07-15 | 2026-07-16 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas Cabozantinib Oral Tablet, Selumetinib Oral Capsule - Neurofibromatosis 1, Plexiform Neurofibroma | Phase 1 | Recruiting | Girish Dhall, MD | 30 | 2026-06-09 | 2026-10-02 |
| Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST APG-115, Selumetinib - Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1) | Phase 1 / Phase 2 | Recruiting | AeRang Kim | 45 | 2026-06-01 | 2026-07-27 |
| DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins Neurofibromas, MPNST | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-04-02 | 2026-09-18 | |
| Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas TQ-B3234 capsules, TQ-B3234 placebo - Plexiform Neurofibroma | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 177 | 2026-03-31 | 2026-05-27 |
| iCanCope With NF: Innovating an Efficacious Digital Self-management and Transitional Care Program for Adolescents With Neurofibromatosis iCanCope-NF Youth app, iCanCope-NF Youth app + CM - Neurofibromatosis 1 | Not applicable | Not yet recruiting | The Hospital for Sick Children | 60 | 2026-03-01 | 2025-07-22 |
| Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis Auto-captioning Glasses - NF2-related Schwannomatosis | Not applicable | Completed | Massachusetts General Hospital | 18 | 2026-02-19 | 2026-08-25 |
Showing 20 of 346. Sign in to see all of them.
Neurofibromatosis 1 (174) · Neurofibrosarcoma (97) · Sarcoma (67) · Neurofibroma, Plexiform (62) · Neurofibromatoses (57) · Neurofibromatosis 2 (47) · Sarcoma, Synovial (47) · Leiomyosarcoma (46) · Histiocytoma, Malignant Fibrous (41) · Liposarcoma (40) · Fibrosarcoma (38) · Hemangiosarcoma (35) · Rhabdomyosarcoma (31) · Neuroma, Acoustic (25)
Neoplasms by Histologic Type (346) · Neoplasms, Nerve Tissue (345) · Nervous System Diseases (345) · Nerve Sheath Neoplasms (339) · Neoplasms (333) · Neuromuscular Diseases (287) · Peripheral Nervous System Diseases (284) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (256) · Neoplastic Syndromes, Hereditary (253) · Genetic Diseases, Inborn (251) · Neurodegenerative Diseases (245) · Heredodegenerative Disorders, Nervous System (244) · Neurocutaneous Syndromes (243) · Nervous System Neoplasms (212)
AZD 6244 (23) · Doxorubicin (17) · Ifosfamide (12) · Radiotherapy (8) · Bevacizumab (7) · Everolimus (7) · Imatinib Mesylate (7) · Sirolimus (7) · trametinib (6) · Lovastatin (5) · mirdametinib (5) · pazopanib (5) · Deoxycholic Acid (4) · Filgrastim (4) · Magnetic Resonance Spectroscopy (4)
National Cancer Institute (NCI) (48) · Massachusetts General Hospital (17) · AstraZeneca (15) · European Organisation for Research and Treatment of Cancer - EORTC (13) · University of Alabama at Birmingham (10) · Memorial Sloan Kettering Cancer Center (8) · NYU Langone Health (6) · Novartis Pharmaceuticals (6) · Assistance Publique - Hôpitaux de Paris (5) · Massachusetts Eye and Ear Infirmary (5) · Sarcoma Alliance for Research through Collaboration (5) · Washington University School of Medicine (5) · Beijing Tiantan Hospital (4) · Children's Hospital Medical Center, Cincinnati (4) · Indiana University (4)
United States (229) · France (27) · United Kingdom (24) · China (23) · Germany (18) · Canada (17) · Belgium (14) · Netherlands (14) · Spain (12) · Australia (9) · Denmark (9) · Japan (7) · Russia (7) · Austria (6) · Italy (6)
Brigitte C Widemann, M.D. (13) · Staci M Peron, Ph.D. (7) · Ana-Maria Vranceanu, PhD (5) · Girish Dhall, MD (4) · AeRang Kim, MD, PhD (3) · Brigitte C. Widemann, MD (3) · Jason R Fangusaro (3) · Matthias A Karajannis, MD, MS (3) · Pamela L Wolters, Ph.D. (3) · Pinan Liu (3) · Richard R Anderson, MD (3) · Scott Plotkin, MD, PhD (3) · Vanessa Merker, PhD (3) · Brigitte Widemann, MD (2)
PMID 28029918, PMID 32187457, PMID 15683544, PMID 17105749, PMID 21996156, PMID 22353803, PMID 26851632, PMID 28230061, PMID 28409229, PMID 31010905, PMID 31401903, PMID 31582003, PMID 33354735, PMID 33863389, PMID 34541874, PMID 35007270, PMID 38908005, PMID 11705489, PMID 12528778, PMID 12957454, PMID 15010069, PMID 15177491, PMID 15592836, PMID 15659504, PMID 16528479, PMID 17095209, PMID 17336054, PMID 17634494, PMID 19088049, PMID 19451429, PMID 19451433, PMID 20434400, PMID 20471824, PMID 21764821, PMID 22934754, PMID 22954508, PMID 23099009, PMID 23382028, PMID 23640206, PMID 24215845, PMID 24321536, PMID 24500418, PMID 24618336, PMID 24747207, PMID 24753394, PMID 25205361, PMID 25858498, PMID 26783591, PMID 26943915, PMID 26976425
U10CA180886 (5), P30CA008748 (3), U10CA098543 (3), N01CM62206 (2), U10CA180821 (2), UM1CA081457 (2), 2009 (1), 2016 (1), 2018 (1), 2023 (1), K08CA245181 (1), K23NS146694 (1), N01CM00071 (1), N01CM17104 (1), N01CM62201 (1)